Drug intelligence / Profile preview

bifidobacterium breve bif11

Development stage: Preclinical
Lead developer: Panjab University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium breve Bif11 is a specific probiotic strain of the species Bifidobacterium breve that has been investigated for its neuroprotective properties, particularly in the context of Parkinson's disease (PD). In preclinical studies using the MPTP-induced rat model of PD, Bif11 supplementation demonstrated the ability to attenuate motor and cognitive impairments. The strain's mechanism of action involves the modulation of the gut-brain axis, leading to increased levels of tyrosine hydroxylase in the midbrain, a reduction in pro-inflammatory markers, and a decrease in oxidative and nitrosative stress. Furthermore, Bif11 helps restore the levels of short-chain fatty acids (SCFAs) and improves intestinal epithelial permeability, addressing the gut dysbiosis and 'leaky gut' often associated with the progression of Parkinson's disease.

Other names: B. breve Bif11

Targets

TH (Tyrosine hydroxylase)

Beyond the preview

Go deeper on bifidobacterium breve bif11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium breve bif11.

Explore the full profile